Jazz Pharmaceuticals plc
JAZZ
#1389
Rank
$16.183 B
Marketcap
Ireland
Country
$249.29
Share price
0.53%
Change (1 day)
90.05%
Change (1 year)
Categories
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the…
Key Metrics
Trailing P/E
16.42
Forward P/E
9.30
EPS (TTM)
$14.60
Forward EPS
$25.77
Price / Book
3.24
EV / EBITDA
9.4x
Beta
0.36
Dividend Yield
—
Return on Equity
22.11%
Return on Assets
6.86%
Debt / Equity
91.83
Current Ratio
1.78
Gross Margin
91.35%
Operating Margin
26.91%
Net Profit Margin
20.45%
Free Cash Flow
$1.429B
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 18
-4.93%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$4.268B
Latest Net Income$-356,148,000
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Jazz Pharmaceuticals plc with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
JAZZ
No recent news available. Set FINNHUB_API_KEY to enable news.
